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Abstract
In recent years, biotechnological breakthroughs have led to identification of complex and unique
biologic  features  associated  with  carcinogenesis.  Tumor  and cell-free DNA profiling,  immune
markers,  and  proteomic  and  RNA  analyses  are  used  to  identify  these  characteristics  for
optimization  of  anticancer  therapy  in  individual  patients. Consequently,  clinical  trials  have
evolved, shifting from tumor type-centered to gene-directed, histology-agnostic, with innovative
adaptive design tailored to biomarker profiling with the goal to improve treatment outcomes. A
plethora  of  precision  medicine  trials  have  been  conducted.  The  majority  of  these  trials
demonstrated that matched therapy is  associated with superior  outcomes compared to non-
matched therapy across tumor types and in specific cancers. To improve the implementation of
precision medicine, this approach should be used early in the course of the disease, and patients
should have complete tumor profiling and access to effective matched therapy. To overcome the
complexity  of  tumor  biology,  clinical  trials  with  combinations  of  gene-targeted  therapy  with
immune-targeted approaches (e.g., checkpoint blockade, personalized vaccines and/or chimeric
antigen  receptor  T-cells),  hormonal  therapy,  chemotherapy and/or  novel  agents  should  be
considered.  These  studies should  target  dynamic  changes  in  tumor  biologic  abnormalities,
eliminating minimal residual disease, and eradicating significant subclones that confer resistance
to  treatment.   Mining  and expansion  of  real-world  data,  facilitated  by  the  use  of  advanced
computer data processing capabilities, may contribute to validation of information to predict new
applications for medicines. In this review, we summarize the clinical trials and discuss challenges
and opportunities to accelerate the implementation of precision oncology. 
Keywords: ctDNA, personalized, precision, molecular profile, matched therapy, genomic 
landscape
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Background
The rapidly expanding body of knowledge about the roles of genomics and the immune system
in cancer has enabled the development of therapies targeted to specific molecular alterations or
other  biologic  characteristics,  such  as  those  implicated  in  immune  suppression.   However,
genomics has also revealed a complicated reality about malignancies that requires a major shift
in the therapy paradigm: away from tumor type-centered and toward gene-directed, histology-
agnostic treatment, which is individualized for each patient on the basis of biomarker analysis.
This paradigm shift is reflected by the emergence of precision medicine trials with innovative
design.  1-21 Next-generation  sequencing  (NGS)  of  advanced  cancers  has  demonstrated  that
genomic alterations  do not  fall  neatly  into categories  defined by the tumor  organ  of  origin.
Furthermore, metastatic tumors harbor tremendously complex and individually unique genomic
and  immune  landscapes.  22,23 Therefore,  in  order  to  target  malignancies  with  “precision,”
treatment needs to be personalized.
Historically, phase II and III oncology clinical trials have measured outcomes histologically,
but  histological  assessment  cannot  always  capture  the  effects  of  gene-targeted  agents  or
immunotherapy. Precision medicine approaches analyze patients’ circulating DNA (liquid biopsy),
as well as immune markers and other biologic features, to assess efficacy and make treatment
decisions.  Genomic biomarkers have been the most successful to date, but other biomarkers,
including protein  assays  and transcriptomics,  are  being developed and tested.  13,24,25 Several
molecular alterations have been identified using sequencing and high-throughput technologies
and have led to the approval of targeted agents by the Food and Drug Administration (FDA). 26,27
Importantly,  in recent years,  the precision medicine paradigm has embraced immunotherapy
and its interaction with genomics,  as genomic characteristics,  such as mismatch repair gene
defects, are critical predictors of checkpoint blockade response. 28-30
Herein, we review the rapid evolution of precision medicine in oncology and, in particular, the 
challenge and opportunity that genomic science has revealed vis-à-vis the need for “N-of-1” 
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treatments. This treatment model does not conform to either canonical trial design or clinical 
practice, which seek to find commonalities between patients and treat them alike; instead, its 
goal is to provide optimized individualized treatment for each patient on the basis of biomarker 
analysis.
History
Survival improvement with gene- or immune-directed therapy was accelerated by several
major  discoveries.  In  particular,  the  introduction  of  imatinib  mesylate  (Abl  tyrosine  kinase
inhibitor)  for  patients  with  Philadelphia  chromosome  [t(9;22)]–positive  chronic  myelogenous
leukemia  producing  the  enzymatically  aberrant  Bcr-Abl 31,32 resulted  in  near-normal  life
expectancy for patients with this previously fatal leukemia.  
In 2001, the human genome was sequenced.  33 Although this milestone represented an
arduous  and  tremendously  expensive  endeavour,  both  the  price  and  time  required  for
sequencing have decreased precipitously, with technology advancing in a manner unparalleled in
human history.  A plethora of first- and second-generation precision medicine trials have since
been conducted (Tables 1 and 2). They include, but are not limited to, the first pan-histology
biomarker-driven  trial  using  mostly  protein  markers,1 the  prospective  molecular  profiling  of
patients with advanced cancer in the phase I clinical trials setting (IMPACT trial)  2,4, the SHIVA
randomized  trial,5 trials  assessing  customized  combinations  6,12,  and  trials  including
transcriptomics. 13
Innovative clinical trial designs for precision medicine
Traditionally,  oncology  trials  are  drug-centered,  aiming  to  identify  common  attributes
among patients (e.g., their tumor type or, more recently, a shared genomic abnormality) and fit
them into  a  trial  with  a  specific  drug  regimen.  The  large  variability  in  genomic  subgroups,
microenvironment,  baseline  characteristics,  comorbidities,  and  other  covariates  resulted  in
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tumor-specific  clinical  studies  encompassing  a  tremendously  heterogeneous  population  in
histology-specific,  gene-agnostic  trials.  Phase  III  randomized  trials  were  often  critical  for
regulatory approval of a novel agent/regimen, especially since the antitumor activity of a new
drug/regimen  was  frequently  only  marginally  better  than  the  comparator  arm  (usually,
conventional therapy), perhaps because the regimen was effective in only a small subgroup of
the diverse population represented by any specific histology.
Basket,  umbrella,  platform,  octopus,  and  master  protocols  :   More  recently,  basket
designs have emerged that target a common genetic defect 27. The 75% objective response rate
noted across tumor types with larotrectinib, which targets  NTRK fusions, best exemplifies the
potential  of  the  basket  gene-directed,  histology-agnostic  model,  though  other  single-gene
targets  have  proven much less  responsive.  27 Umbrella  trials  involve  a  single  histology  and
different treatments based on the genomic alterations in patient subgroups. 34 Other trial designs
include platform trials, which use a single analytic technique, such as NGS, to identify genomic or
other  biomarkers  in  tumors  with  multiple  histologies;  octopus  trials  (also  referred  to  as
“complete phase I  trials”) that have multiple arms testing different combinations featuring a
particular  drug;  and  master  protocols,  which  encompass  trials  with  several  histologic  arms
(previously, “broad phase II trials”) or multiple platform, basket, or umbrella trials or sub-trials. 2-
4,6 Randomization has also evolved, with the emergence of  Bayesian adaptation, which allows
dynamic  modifications  of  randomization  based  on  small  numbers  of  patients  and  real-time
outcomes.    
From drug-centered to patient-centered studies: The ultimate goal of precision medicine is
an individualized, patient-centered (rather than drug-centered) trial based on the best available
biomarkers. In “N-of-1” trials, each patient’s treatment is considered separately on the basis of
molecular,  immune,  and  other  biologic  characteristics.  These  trials  involve  customized  drug
combinations tailored to individual patients.  12 Determining efficacy in “N-of-1” trials requires
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assessing the “strategy” of matching patients to drugs, rather than treatments, which differ from
patient to patient.
Real-world data:  With advanced computer data “processing” capabilities, real-world registries
and data mining are expanding. Two drug approvals by the FDA were based, at least in part, on
such  data:  pembrolizumab  for  any  solid  tumor  with  a  mismatch  repair  gene  defect
(https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm56004”0.htm) and
palbociclib  for  male  breast  cancer
(https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635276.htm).  The
stunning possibility exists that real-world data, if confirmed to accurately portray the anticipated
results of prospective trials, will dramatically accelerate the drug approval process. 
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Genomic and other biomarkers
Genomics has been the cornerstone of precision medicine studies. Beyond genomics, RNA
and protein profiling, with proteins being the effectors of signaling, also appear to be important
in mediating biologic impact. Interestingly, matching patients to drugs on the basis of genomics
has proven more effective in improving outcome than matching on the basis of protein assays,
perhaps for technical reasons 24.  Despite the current practical limitations, protein and transcript
assays may provide essential information when integrated with genomics.  13 Recently, panels
that  incorporate  immune signatures,  based on DNA,  RNA,  and/or  proteins,  have also gained
clinical significance. 35  
Genomics: Given the advances in NGS technologies and the large number of laboratories in the
US that perform Clinical Laboratory Improvement Amendments (CLIA)-certified NGS, optimization
of the accuracy, reproducibility, and standardization of sequencing methods; variant annotation;
and  data  interpretation  is  critical.  Guidelines  for  the  validation  of  NGS  panels  36 and  the
interpretation  and  reporting  of  genomic  variants  have  been developed  37.   Although whole-
genome sequencing is not yet the standard practice in the clinic, the FDA has approved two NGS
panels that include hundreds of genes. 38
Most  genomic  sequencing  involves  tissue,  but  blood-derived  circulating  tumor  DNA
(ctDNA), circulating tumor cells  39, and exosomes  40 are increasingly used, with the latter two
reflecting the contents of live cells.
Blood-derived cell-free DNA analysis: Clinical-grade ctDNA testing,  which is  non-invasive and
reflects tumor heterogeneity (because tumor DNA may be leaked into the bloodstream from
multiple  metastatic  lesions),  is  increasingly being  used to  select  anti-cancer  therapy and to
monitor subclone dynamics during treatment.41,42 The discordance noted in some cases between
results of ctDNA testing and tumor tissue genotyping analysis 43 could reflect technical issues but
might be attributable to the following biologic reasons: (i) tumor NGS measures genomics in the
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small piece of tissue biopsied while ctDNA assesses shed DNA from multiple sites; (ii) ctDNA is
associated with tumor load and can be detected at low levels.
Blood-derived   circulating tumor cell (CTC) analysis:   The presence of CTCs, which are epithelial
tumor cells, has been independently associated with worse survival in several types of cancer. 44-
46  For example, in a prospective, multicenter, double-blind study, the number of CTCs in patients
with untreated metastatic breast cancer correlated with shorter progression-free survival (PFS)
and overall  survival (OS).  44 CTCs may also be a predictive biomarker for chemotherapy and
immunotherapy. 45,47 However, the use of CTCs in clinical practice has not been fully established.
48 Finally, serial CTC analyses might enable real-time surveillance of the disease. A comparative
study of five prospective randomized phase III trials in 6,081 patients with metastatic castration-
resistant prostate cancer assessed the prognostic value of CTCs compared to prostate-specific
antigen. 49 CTC ≥0 at baseline and at week 13 from treatment initiation was associated with OS.
The investigators  demonstrated  that  CTC monitoring was  a robust  and meaningful  response
endpoint for early-phase clinical trials in this setting. 49 
Transcriptomics: Transcriptomics  refers  to  the study of  RNA transcripts  and their  function.
Transcriptomic analysis is performed using high-throughput technologies, including microarrays
and RNA sequencing and it is a potentially valuable tool, particularly when there is discrepancy
between  genomic  alterations  and  gene  expression.  Transcriptomics  are  utilized  to  identify
prognostic and predictive gene expression signatures  50,51, to explore miRNAs and their role in
mRNA regulation 52,53 and to identify the tissue of origin in cancer of unknown primary.54-56 The
first  solid  tumor  precision  medicine  trial  to  use  transcriptomics  in  the  clinic---WINTHER---
compared RNA expression in tumors to that in adjacent normal tissue and demonstrated that
transcriptomics  increased  the  number  of  patients  that  could  be  matched  to  therapy.  13
Comparing tumor to normal tissue from the same patient may be necessary because of the large
inter-patient  variability  in  normal  RNA  expression.  Other  investigators  have  also  used
transcriptomics  to  select  targeted  treatments  in  patients  with  advanced  solid  tumors.  57,58
10
Challenges  that  prevent  extensive  use  of  transcriptomic  biomarkers  are  degradation  and
fragmentation  of  RNA  in  formalin-fixed,  paraffin-embedded  tissue  samples,  complexity  of
required bioinformatic analysis of profiling data and low reproducibility of the results. 
Proteomics: Proteomic analysis using immunohistochemical and other assays of tumors from
patients with refractory metastatic cancer led to the identification of molecular targets that could
guide therapeutic decisions and was associated with longer PFS compared to the patients’ PFS
with their prior therapy (using patients as their own controls).1 Proteomic assays are used in
clinical practice to identify prognostic or predictive biomarkers for targeted treatments (hormone
receptor expression, HER2 overexpression, ALK expression). However, the weaker correlation of
proteomic  markers,  compared  to  genomic  markers,  with  clinical  outcomes  suggests  that
technical  issues should be addressed.24 In  a  meta-analysis  of  phase 1 clinical  trials  of  small
molecules that used a genomic biomarker vs. those that used a protein biomarker, the median
response  rate  was  41%  vs.  25%,  respectively  (p  =  0.05).24 Ongoing  studies  with  targeted
therapies  include  correlative  analyses  using  peripheral  blood  and  tumor  tissue  to  identify
proteomic  biomarkers  of  response  or  resistance  to  treatment  (LEEomic,  NCT03613220  and
BABST-C, NCT03743428).
Immunotherapy and cellular therapy
By reactivating the innate immune antitumor response,  immunotherapy has provided a
major breakthrough in oncology treatment.  28,59 Several  novel approaches are currently being
explored: checkpoint blockade, oncolytic viruses, cell-based products, modified cytokines, CD3-
bispecific antibodies, vaccine platforms, and adoptive cell therapy. 60 
Checkpoint  blockade: There  are  seven  FDA-approved  checkpoint  inhibitors:  ipilimumab,
pembrolizumab,  nivolumab,  avelumab,  cemiplimab,  durvalumab,  and  atezolizumab.  Selected
patients with advanced disease have remarkable response, including durable complete remission
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(CR).  Despite the significant  benefit noted in patients with diverse tumor types treated with
checkpoint inhibitors, approximately 80% of patients across cancers do not experience beneficial
effects. In the era of precision medicine, genomics, transcriptomics and other technologies are
employed  for  the  identification  of  biomarkers  that  predict  benefit  from  immunotherapy.
Interestingly, biomarkers predicting checkpoint inhibitor responsiveness are genomic: high tumor
mutational  burden (TMB)  28,59,61,  mismatch gene repair defects resulting in high microsatellite
instability (MSI-H) (and, thus, high TMB)  29,62,  PBRM1 alterations  63,64, and  PDL1 amplification.  65
Specifically, TMB has been shown to predict clinical benefit from checkpoint inhibitors.  28 In an
analysis of 151 of 1638 patients who were treated with immunotherapeutic regimens and had
TMB evaluation, high (≥ 20 mutations/mb) TBM was independently associated with significant
improvement  in  PFS  and  OS  compared  to  low  to  intermediate  TMB.  28 Other  studies  have
however questioned the use of TMB as a biomarker. 66,67
Given its  strong association  with response to immunotherapy,  MSI-H is  an established
biomarker  for  response  to  checkpoint  inhibitors.  68,69 MSI-H  tumors  have  high  TMB,  often
accumulating >1,000 non-synonymous genomic mutations, leading to tumor-specific proteins,
known as neoantigens.  Due to high clinical  benefit rates,  immunotherapeutic regimens have
been approved by the FDA for the treatment of patients with advanced MSI-H colorectal cancer
70-72 or MSI-H tumors, irrespective of the organ of origin. 73 Finally, defects in DNA proofreading
proteins  polymerase  δ  (POLD1)  and  polymerase  ε  (POLE)  lead  to  increased  TMB  and  are
associated with response to immunotherapy. 59,74,75 For instance, of 4 patients with non–small cell
lung cancer with deleterious mutations in POLD1 and POLE (whole-exome sequencing, [WES]), 3
patients  with  the  highest  TMB responded to  pembrolizumab.  59 Defects  in  other  DNA repair
systems  might  also  be  associated  with  response  to  immunotherapy.  The  predictive  role  of
homologous  recombination  deficiency  (HRD)  is  being  evaluated  in  various  tumors,  including
breast  and ovarian cancer.  Early phase clinical  trials  demonstrating that these patients  may
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benefit from the addition of immunotherapy to poly ADP-ribose polymerase (PARP) inhibitors,
should be confirmed with additional studies. 76,77 
Furthermore,  PBRM1  molecular  alterations  are  evaluated as  genomic  biomarkers
predicting checkpoint inhibitor responsiveness. Specifically, PBRM1 alterations were evaluated in
a study of 35 patients with metastatic renal cell cancer treated with anti-programmed death-1
(PD-1)  regimens.  63 WES  revealed  loss-of-function  (LOF)  mutations  in  the  PBRM1  gene  that
predicted response to immunotherapy. Notably, the PBRM1 gene encodes for a protein of the
chromatin  remodeling  complex,  possibly  interfering  with  hypoxia,  and  immune  signaling
pathways. 63 
Another biomarker that predicts benefit from immunotherapy is PD-L1 amplification. 65 In a
retrospective analysis, this marker was identified in 0.7% (843 of 118,187) patients of various
tumor types and it did not always correlate with PD-L1 expression. Six of 9 (66.7%) patients with
PD-L1-amplified  solid  tumors  had  an  objective  response  to  checkpoint  inhibitors,  and  their
median PFS was 15.2 months. 65 PDL1 expression, assessed by immunohistochemistry on tumor
cells  or  immune  cells   can  be  used  as  a  response marker,  albeit  a  suboptimal  one.  78
Approximately 20% of FDA approvals of immunotherapeutic agents are based on companion PD-
L1 diagnostic testing. 79
Genomic  markers  may  also  predict  resistance---loss  of  JAK2  and beta  2  microglobulin
mutations 80—or hyper-progression (accelerated progression) after checkpoint blockade---MDM2
amplification  and  EGFR  alterations.  81 WES  of  tumor  tissue  from  4  patients  with  advanced
melanoma whose disease was resistant to anti–PD1 therapy, demonstrated LOF mutations in
genes  involved  in  interferon-receptor  signaling  and  in  antigen  presentation  (JAK1/2,  β2-
microglobulin).  80 Importantly,  PTEN  loss  is  associated  with  resistance  to  immunotherapy  in
patients with melanoma, suggesting that targeting the PI3K/AKT/mTOR pathway may overcome
resistance to immunotherapy. 82 In our opinion, it is plausible that when PI3K/AKT/mTOR pathway
alterations or PTEN loss are the key drivers of the disease, immunotherapy may have limited, if
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any,  antitumor  activity.  Similarly,  STK11  mutations  and  β-catenin  pathway  alterations  are
reportedly associated with resistance to immunotherapy. 83,84
In summary, the available biomarkers are insufficient to adequately predict response to
immunotherapy. Novel strategies may enhance our ability to identify biomarkers longitudinally,
incorporating ctDNA analysis 85 or tumor tissue immune, genomic, transcriptomic, and proteomic
analysis.
Adoptive cell therapy
Adoptive  cell  therapy  (ACT)  is  an  innovative  personalized  treatment  approach  that
enhances a patient’s immune system leading to specific tumor cell killing. Immune cells derived
from a patient’s blood or tissue are expanded in vitro and then reinfused into the patient. These
immune cells  may be reprogrammed to recognize tumor-specific antigens.  60,86 Types of ACT
include  tumor-infiltrating  lymphocyte  (TIL)  therapy,  chimeric  antigen  receptor  (CAR)  T-cell
therapy, engineered T-cell receptor (TCR) therapy and natural killer (NK) cell therapy.
TILs: ACT of TILs is based on the use of T-cells that have infiltrated a patient’s tumor. Autologous
cells are being harvested and administered to patients after their expansion and activation. This
approach  has  shown  promising  results  in  metastatic  melanoma  87-90,  nasopharyngeal,  and
cervical carcinoma.  91,92 In three sequential clinical trials in patients with metastatic melanoma
who had  failed  standard  therapy,  the  use  of  autologous  TILs  was  associated  with  objective
response rates of 49%, 52%, and 72%, respectively; durable CRs were reported in 22% (20 of 93)
of patients; and clinical benefit was observed irrespectively of prior therapy.87 Ongoing clinical
trials  assess  the  role  of  TIL  therapy  in  various  solid  tumors  (NCT03645928,  NCT03935893,
NCT03108495, NCT03083873). 
CAR  T-cells: CAR  T-cells  are  a  type  of  adoptive  T-cell  therapy  in  which  autologous  T-
lymphocytes are genetically engineered to recognize the antigens expressed on malignant cells.
93 Adoptive T-cell therapy has resulted in remarkably high rates of durable CR in hematologic
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malignancies, including in patients with refractory disease. Therefore, the FDA has approved CAR
T-cells for the treatment of pediatric patients and young adults with relapsed/refractory B-cell
precursor  acute  lymphoblastic  leukemia  (Kymriah™,  https://www.fda.gov/drugs/resources-
information-approved-drugs/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-
cell-lymphoma)  and  adult  patients  with  relapsed/refractory  diffuse  large  B-cell  lymphoma
(Yescarta™,  https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/
yescarta-axicabtagene-ciloleucel). CAR T-cells are currently being evaluated in solid tumors. 94,95
TCR  therapy: This  approach  uses  T-cell  receptor  (TCR)  engineered  T-cells, and  involves
retroviruses  that  enable  integration  of  new  TCR  transgene  targeting  antigens,  which  are
expressed at high levels on different cancers into the genome of T-cells. 96  TCR therapy has
been assessed in hematologic and solid malignancies.  97-101 Current trials evaluate treatment-
associated toxicity, binding affinity to tumor antigens and efficacy in carefully selected patients
with increased tumor burden. 
NK cell therapy: Natural killer (NK) cells are cytotoxic lymphocytes that play a critical role in
innate immunity. NK cells do not cause graft-versus-host disease, which makes them promising
candidates for cancer treatment. Treatment of relapsed/refractory acute myeloid leukemia with
haploidentical NK cells and recombinant human interleukin-15 induced CR in 32% of patients.102
Clinical  trials  are  currently  evaluating  CAR-NK  cells  in  hematologic  (NCT03056339,
NCT00995137) and solid (NCT03656705, NCT03383978) malignancies.
Personalized vaccines (vaccinomics): The accumulation of somatic mutations in cancer can
generate cancer-specific neo-epitopes. Autologous T-cells often identify these neo-epitopes as
foreign bodies, which makes them ideal cancer vaccine targets. Every cancer has its own unique
mutations,  but  a small  number  of  neo-antigens  are  shared between cancers.   Theoretically,
technological advances will soon result in rapid mapping of mutations within a genome, rational
selection  of  vaccine  targets  such  as  neo-epitopes,  and  on-demand  production  of  vaccines
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tailored  to  a  patient's  individual  tumor.  Alternatively,  off-the-shelf  vaccines  for  tumors  with
shared epitopes might also be exploitable.  
Several  personalized  vaccines  are  currently  being  evaluated  in  clinical  trials.103,104 For
example,  investigators  used computational  prediction of  neo-epitopes to design personalized
RNA mutanome vaccines for  patients  with  metastatic  melanoma.103 Two of  the five patients
treated had objective responses to the vaccine alone, while a third patient had a CR to treatment
with  the  vaccine  combined  with  PD-1  blockade.  103 In  another  study  of  vaccine-induced
polyfunctional  CD4+  and  CD8+  T-cells  targeting  unique  neoantigens  in  patients  with
melanoma104, four of six vaccinated patients had no recurrence at 25 months after vaccination.
104
Sipuleucel-T, the first FDA-approved therapeutic cancer vaccine, is produced via  ex vivo
activation  of  autologous  peripheral-blood  mononuclear  cells  by a recombinant  fusion protein
comprised of prostatic acid phosphatase and granulocyte–macrophage colony-stimulating factor.
105 Sipuleucel-T is used to treat metastatic castration-resistant prostate cancer on the basis of
results of a randomized, double-blind, placebo-controlled phase III  trial in which patients who
received Sipuleucel-T had longer survival than those who received placebo (25.8 months vs. 21.7
months, respectively; p=0.03). 105
Challenges and solutions for the optimal implementation of precision medicine 
Genomic studies have unveiled the reality of tumors—they are tremendously heterogenic
and complex, and optimized therapy often does not result from classical clinical research and
practice models.
Precision  medicine  studies  (Tables  1  and  2) demonstrate  the  major  challenges  in
designing trials for this new paradigm. First, the rate of matching patients to drugs in these trials
ranges from 5% to 49% and is mostly in the 15% to 20% range.  Failure to match patients is
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attributed to (i) enrollment of individuals with end-stage disease, who deteriorate or die early; (ii)
use of small gene panels that yield limited actionable alterations; (iii) delays in receiving and
interpreting genomic results; and (iv) difficulty accessing targeted therapy drugs and/or limited
drug availability. Some solutions provided by trials with higher matching rates, e.g., I-PREDICT 12
(matching  rate,  49%),  include:  (i)  use  of  clinical  trial  navigators  and  medication  acquisition
specialists; (ii) application of a large NGS panel with >200 genes; (iii) creation of just-in-time
electronic molecular tumor boards immediately upon physician request; and (iv) exploitation of
biomarkers  to  match  patients  to  chemotherapy,  hormonal  therapy,  and  immunotherapy  (in
addition to gene-targeted agents). The majority of these trials 2,3,12,24 have shown improvement in
clinical  outcomes  when  treatments  are  matched  to  drugs  compared  to  when  they  are  not.
Importantly,  malignancies  have  complicated  molecular  biology,  and  use  of  personalized
combinations  of  drugs  that  address  a  higher  percentage  of  the  aberrations  present  in  an
individual cancer is associated with better outcomes than more limited matching. 6,7,12,13 
Other major hurdles encountered in the implementation of precision medicine include the
following: (i) Potential differences in response to matched therapy depending on histology and/or
genomic  co-alterations.  In  contrast  to  molecular  abnormalities  that  predict  tumor  agnostic
response  to  treatment  (e.g.,  NTRK  fusions,  MSI-H)  27,71,73,  selected  genomic  biomarkers  are
predictive in specific tumor histologies.  106,107 (ii)  The heterogeneity, complexity, and constant
evolution of genomic landscapes. Due to significant heterogeneity between primary tumor and
metastatic sites, molecular profiling of tumor tissue obtained from a single lesion may not always
be  representative  of  the  systemic  disease.108,109 Additionally,  under  the  pressure  of  targeted
treatments, tumor molecular profile constantly evolves, with emerging resistant clones and new
molecular alterations driving disease progression.110,111 (iii) The need to screen large numbers of
patients in order to find specific/rare genomic defects (for instance, NTRK fusions).  27,106,107 (iv)
Incomplete biologic/molecular profiles with which to select therapy; suboptimal technology and
resources to understand completely the drivers of cancer in individual patients; (v) Considerable
delays in the activation of clinical trials; (vi) differences in the metabolism and adverse effects of
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study drugs in various ethnic  groups;  (vii)  lack of  agreement between assays from different
diagnostic  companies/laboratories;  and  (viii)  most  importantly,  lack  of  access  to  drugs  for
patients with limited resources as well as excessive eligibility criteria that rule out large swaths
of  patients  with  real-world  co-morbidities.  Approximately  3-5%  of  patients  with  cancer  are
enrolled on clinical trials and accrual is limited by overly restrictive eligibility criteria and limited
access to drugs.112 ASCO, the Friends of Cancer Research, and the FDA recommended to broaden
eligibility criteria to allow more patients to participate in clinical trials and gain benefit from novel
investigational therapies;113 and consequently participants will be representative of the actual
patient  population,  increasing  generalizability  of  the  results.  Patient  enrollment  could  be
enhanced by national  and worldwide collaborations, as shown in multi-institutional trials.114,115
Finally, the Clinical Trials Transformation Initiative (CTTI), has been developed to examine the
challenges and propose solutions to improve trial recruitment. 116
Several  initiatives  might  help  overcome  the  challenges  introduced  by  our  emerging
understanding of cancer biology: (i) molecular profiling (tissue, blood) should be used at the time
of diagnosis and during the course of the disease, the latter to monitor response and resistance;
(ii) completion of molecular profiling should be expedited; and (iii) bioinformatic analysis should
be optimized to include the key drivers of carcinogenesis.
With the current excitement about the promise of immunotherapy, a large proportion of
patients are assigned to immunotherapy trials without undergoing molecular profiling or immune
marker identification. Although a significant minority of these patients will experience a clinical
benefit  and prolonged survival,  the majority  will  have disease  progression  and/or  significant
adverse events.  Therefore,  the incorporation  of  biomarkers into the selection of  patients  for
immunotherapy needs to be optimized.
Finally,  the immense potential  of  real-world data needs to be addressed. Validation of
database  information can  be performed by comparing outcomes of  clinical  trials  that  led to
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approval with those in the database; if outcomes are similar, real-world data can then be used to
rapidly predict new applications for medicines.
Conclusions and future perspectives
Remarkable biotechnological advances are transforming cancer care. Tumor and cell-free
DNA profiling using NGS, as well as proteomic and RNA analysis, and a better understanding of
immune  mechanisms  are  optimizing  cancer  treatment  selection.  A  major  challenge  in  the
therapeutic management of patients with advanced metastatic cancer is the complexity of tumor
biology.  This  complexity  is  attributed  to  highly  variable  patterns  of  genetic  and  epigenetic
diversity and clonal  architecture  associated with spatial expansion, proliferative self-renewal,
migration, and invasion. The complexity is amplified by the dynamic, Darwinian evolutionary
character  of  cancer  cells,  which  undergo  sequential  searches  for  mechanisms  to  escape
environmental  constraints.  Such  cellular  evolution  involves  the  interplay  of  advantageous
“driver” lesions, neutral or “passenger/hitchhiker” abnormalities, molecular changes in the tumor
cells  that  increase  the  rate  of  other  genomic  anomalies,  and  modifications  to  the
microenvironment and immune machinery that  alter the fitness effects  of  other variables.117
Strategies to  address tumor  complexity  include targeting self-renewing cancer  stem cells  to
overcome their plasticity and adaptability, impacting the microenvironment, and turning cancer
into a chronic disease (using cytostatic drugs to suppress cell division and new mutations). The
complicated nature of tumor biology is also the result of  interactions between the tumor, host,
and  local  ecosystem,  including  HLA  type,  genetic  polymorphisms,  microbiome,  immune  cell
repertoire, and tumor microenvironment.118 New strategies, some of which now have a proven
track record, include gene-directed therapies and a host of immune-targeted approaches (e.g.,
checkpoint blockade, CAR T-cells, personalized vaccinomics). 118,119 
An  overarching  theme  is  that  optimized  therapy  may  require  the  utilization  of
combinations of drugs and/or strategies that attack the tumor from multiple angles. It is time to
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recognize the possibility that advanced computer implementation could generate real-world data
that  expand  our  understanding  of  cancer,  rapidly  identify  new  treatments,  and  create
personalized drugs or immune therapies. 
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Table 1:  Examples of Precision Medicine Trials: Design and Outcomes
Year
First/Last 
author
Trial name Trial type No of 
pts 
screen
ed (N)
Proportion
of pts. 
matched
Biomarker(s
)
Outcome Institute(s) Comments
Diverse treatment-refractory tumor types 
20101
Von Hoff D
Penny R
Bisgrove Prospectiv
e, 
navigation
al
86 77% IHC, FISH, 
microarray
27% of 66 matched 
pts had a PFS2/PFS1 
ratio* ≥1.3 (95% CI, 
17% to 38%; p = 
0.007). 
US 
(9 sites)
20122
Tsimberidou 
A
Kurzrock R
IMPACT, 
first 
cohort
Registry 
type,
Navigation
al
1144 15% PCR-based 
genomics, 
9 genes
Matched vs 
unmatched 
RR, 27% vs. 5% 
(p<0.0001), 
TTF: median, 5.2 vs. 
2.2 mos (p<0.0001)
OS: median, 13.4 vs. 
9.0 mos (p = 0.017)
MD Anderson
Cancer 
Center
20143
Tsimberidou 
A Berry D
IMPACT, 
second 
cohort
Registry 
type,
navigation
al
1276 11% PCR-based 
genomics, 
18-50 
genes
Matched vs 
unmatched 
RR, 11.9% vs. 5% 
(p<0.0001), 
PFS: median, 3.9 vs. 
2.2 mos, (p=0.001); 
OS: median, 11.4 vs. 
8.6 mos (p=0.04)
MD Anderson
Cancer 
Center
2-month 
landmark 
analyses, 
matched therapy 
group: OS, 
responders 30.5 
months vs. 11.3 
months for non-
responders (p = 
0.01).
20174
Tsimberidou 
AM
Kurzrock R
IMPACT, 
third 
cohort
Registry 
type,
navigation
al
1436 27% PCR-based 
genomics 
and NGS, 
11 to 182 
genes
Matched vs 
unmatched 
Higher rates of ORR 
(p=0.0099), TTF 
(p=0.0015), and OS 
(p=0.04)
MD Anderson
Cancer 
Center
20155
Le Tourneau
Paoletti X
SHIVA Prospectiv
e,
randomize
741 13% Targeted 
NGS, ~50 
genes
PFS not improved 
with matched 
therapy (p=0.41)
Institut 
Curie, 8 
French sites
~80% of patients 
received single-
agent hormone 
22
d modulators or 
everolimus
20166
Schwaederle 
M
Kurzrock R
PREDICT Registry 
type 
347 25% NGS, 182 
or 236 
genes
Matched vs 
unmatched
Higher rates of SD≥ 
6 months/PR/CR 
(p=0.02) and PFS 
(p<0.04). Higher 
matching scores 
correlated with 
better OS: 15.7 vs 
10.6 mos (p=0.04)
University of 
California 
San Diego
20167
Wheler JJ
Kurzrock R
MD 
Anderson 
Personaliz
ed Cancer
Therapy 
Initiative
Prospectiv
e,
navigation
al
500 24% NGS,
236 genes
Higher matching 
scores correlated 
with higher rates of 
SD ≥6 months/PR/CR
(p= 0.024), TTF (p= 
0.0003), and OS (p= 
0.05)
MD Anderson
Cancer 
Center
20168
Stockley TL
Bedard PL
IMPACT/
COMPACT
Prospectiv
e
1893 5% Hot spot 
panel,
23 genes
Matched vs 
unmatched
Higher ORR: 19% vs 
9%, (p=0.026).
Princess 
Margaret, 
Canadian 
centers
20179
Massard C
Soria JC
MOSCATO Prospectiv
e
1035 19% Targeted 
NGS,
40-75 
genes;
aCGH; 
RNAseq
PFS2/PFS1 ratio* was
>1.3 in 33% (63/193)
of patients 
Institut 
Gustave 
Roussy
201810
Hainsworth JD
Kurzrock R
MyPathwa
y
Prospectiv
e, Phase 2 
basket
251 Not 
available
Genomic 
testing via 
any CLIA 
lab
Matched patients, 
ORR:
All, 23% 
HER2-altered, 38%
BRAF-altered, 43%
Multiple 
sites, 
Genentech
251 patients 
enrolled; 230 
were treated; 
however, how 
many were 
screened pre-
enrollment is 
unknown
201911 Profiler Prospectiv 2579 6% NGS, 69 RR = 13% (23 of 182 Four 
23
Tredan O
Blay JY
e genes treated) institutes 
(France)
201912
Sicklick J
Kurzrock R
I-PREDICT Prospectiv
e,
navigation
al
149 49% NGS, 315 
genes;
ctDNA; 
PDL1 IHC
Higher matching 
scores correlated 
with increased rates 
of SD>6 months/PR/
CR: 50% vs 22.4% 
(p=0.028), PFS 
(p=0.0004), and OS 
(p=0.038)
University of 
California 
San Diego 
and Avera
First trial to 
administer 
customized 
combination 
therapy (“N-of-1” 
matching)
201913
Rodon J
Kurzrock R
WINTHER Prospectiv
e, 
navigation
al
303 35% NGS, 236 
genes;
transcripto
mics
Higher matching 
scores correlated 
with longer PFS 
(p=0.005) and OS 
(p= 0.03)
Five 
countries 
(Spain, 
Israel, 
France, 
Canada, US)
First solid tumor 
trial to include 
transcriptomics
Specific tumors—Lung
201114
Kim ES
Hong WK
BATTLE Prospectiv
e,
adaptive, 
randomize
d
255 Not 
available
11 
biomarkers
8-week disease 
control rate, 46%
MD Anderson
Cancer 
Center
It is unclear how 
many patients 
were screened 
before consent
201415
Kris MG
Bunn PA
Lung 
cancer 
mutation 
consortiu
m
Prospectiv
e
1537 17% Multiplex 
genotyping
,
10 genes
Improved OS with 
matched vs 
unmatched therapy 
(p=0.006)
14 US sites
201616
Aisner D
Kwiatkowski 
DJ
Lung 
Cancer 
Mutation 
Consortiu
m II
Prospectiv
e
904 12% NGS, 
minimum 
of 14 genes
Improved survival 
with matched 
therapy (p<0.001)
16 sites
201617
Papadimitrak
o-poulou V
Herbst RS
BATTLE-2 Prospectiv
e,
adaptive, 
randomize
d
334 Non-
applicable
ALK, FISH,
EGFR, and 
KRAS 
Sanger 
sequencing
KRAS alterations: 
longer PFS without 
erlotinib (p=0.04); 
KRAS wild-type 
tumors: longer OS on
erlotinib (p=0.03)
MD Anderson
Cancer 
Center
24
Specific tumors—Breast
201218
Esserman LJ
Hylton N
I-SPY 1 Neoadjuva
nt,
correlative
237 Non-
applicable
IHC pCR differs by subset Multiple US 
sites
Aim was to 
develop 
biomarkers of 
response to 
conventional 
therapy
201519
Andre F
Bonnefoi H
SAFIR01/
UNICANCE
R
Prospectiv
e
423 13% Sanger 
sequencing
(2 genes: 
PIK3CA and
AKT); aCGH
Matched group, ORR 
9%
18 centers in
France
201620,21
Park JW
Berry DA
Rugo HS
Esserman LJ
I-SPY 2 Phase 2 
adaptive 
design, 
neoadjuva
nt
Non-
applic
able
Non-
applicable
IHC, 
Mammapri
nt
Improved pCR rates 
in 2 study arms with 
drug addition: 
HER2+, hormone 
receptor-negative:  
neratinib plus 
standard therapy 
(N=115) vs standard 
therapy (N=78): 56%
vs 33%
Triple–negative: 
veliparib plus 
carboplatin (N=72) 
with standard 
therapy vs standard 
therapy (N=44): 51%
vs 26% 
Quantum-
Leap 
Healthcare
(US sites)
Results for 2 arms
of I-SPY-2 study 
available
Specific tumors—Gastric
2019120
Lee J
WK Kang
VICTORY Prospectiv
e
772 14% NGS, IHC, 
PDL1, MMR 
and EBV 
status
Improved PFS and OS
with matched vs 
unmatched therapy 
(p<0.0001)
Republic of 
Korea
The trial included 
10 phase II trials 
that operated 
independently 
(based on eight 
biomarkers)
25
*PFS2/PFS1 ratio is defined by the PFS on the trial versus the PFS on the therapy immediately preceding the trial; in general, 
PFS is shorter with every subsequent therapy
**Οnly studies published as manuscripts, not just as abstracts, included
Abbreviations: aCGH=array comparative genomic hybridization, ASCO=American Society of Clinical Oncology, 
CLIA=clinical laboratory improvement amendment, cDNA MA=cDNA microarray, CGP=comprehensive genomic profiling, 
CR=complete remission, ctDNA=circulating tumor DNA, FISH=fluorescence in situ hybridization, 
IHC=immunohistochemistry, mos=months, NGS=next-generation sequencing, ORR=overall response rate, OS=overall 
survival, pCR=pathological complete response, PCR=polymerase chain reaction, PFS=progression-free survival, PR=partial 
remission; pts=patients, RR=response rate, RRPA=reverse phase protein array, SD=stable disease, TTF=time to treatment 
failure
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         Table 2: Selected ongoing studies of precision medicine 
Year
started Trial name Trial type Cancer type Biomarker
NCT
number Institute(s) Comment
201020,21 I-SPY 2 Prospective
randomized
Neoadjuvant 
breast cancer
IHC, 
Mammaprint
NCT0104237
9
Quantum-Leap
Healthcare, US
sites
Ongoing study
with 
preliminary 
results (see 
Table 1)
2012121 SPECTA-
Color
Registry 
type
Advanced 
colorectal cancer
NGS/IHC NCT0172396
9
European 
hospitals
2013 MPACT Prospective Advanced cancer NGS NCT0182738
4
NCI, US sites
2014122 ALCHEMIST Prospective Early stage non-
small cell lung 
cancer
Direct 
sequencing, 
FISH, CLIA 
certified 
genotyping
NCT0219473
8
NCI, US sites
201434 Lung-MAP Prospective Advanced 
squamous cell 
lung cancer
NGS NCT0215449
0
NCT0278591
3
NCT0296537
8
NCT0278593
9
NCT0278595
2
NCT0292663
8
NCT0276633
5
NCI, US sites
27
2014123 AURORA Registry 
type
Metastatic breast
cancer
NGS/RNAseq NCT0210216
5
Institut Jules 
Bordet, 
Brussels, 
Belgium, 
European 
hospitals
2014124 Signature Prospective Advanced 
cancers
Variable NCT0218778
3
NCT0218682
1
Novartis, 
multiple sites
201410 MyPathway Prospective Advanced 
cancers
Genomic 
testing
NCT0209114
1
Genentech,
US sites
2014 IMPACT2 Prospective
, 
randomized
Metastatic 
cancer
Genomic 
testing
NCT0215225
4
MD Anderson 
Cancer Center
2014125 Pangea Prospective
Gastro-
esophageal 
adenocarcinoma
Tumor 
biomarker 
profiling/cell-
free DNA
NCT0221328
9
University of 
Chicago
2015126-129 NCI-MATCH Prospective Advanced 
cancers
NGS NCT0246506
0
NCI, US sites
201512 I-PREDICT Prospective
navigationa
l
Advanced 
cancers including
treatment-naïve 
patients
CGP NCT0253467
5
UC San Diego
Avera
Ongoing study
with 
preliminary 
results (see 
Table 1)
2016 DART Prospective Rare cancers
NGS 
correlational 
testing: whole
genomic, 
NCT0283401
3
SWOG/NCI, 
multiple US 
sites
28
transcriptome
, liquid biopsy
(ctDNA), and 
immune 
signature
2016130 TAPUR Prospective Advanced 
cancers
Genomic 
analysis or 
IHC
NCT0269353
5
ASCO, US sites
2016 DRUP Prospective Advanced 
cancers
NGS NCT0292523
4
Netherlands
2017 Pediatric 
MATCH
Prospective Pediatric 
advanced 
Cancers
CLIA-certified 
molecular 
testing
NCT0315562
0
NCI-COG, US 
sites
2018
Columbia 
University 
N-of-1 
Clinical 
Trials
Prospective Metastatic cancer
Computationa
l strategies 
(OncoTarget 
and 
OncoTreat)
Columbia 
University
Abbreviations: aCGH=array comparative genomic hybridization, ASCO=American Society of Clinical Oncology, 
CGP=comprehensive genomic profiling, CLIA=Clinical Laboratory Improvement Amendments, COG=Children’s 
Oncology Group, FISH=fluorescence in situ hybridization, IHC=immunohistochemistry, NCI=National Cancer 
Institute, NGS=next-generation sequencing, RNA seq=RNA sequencing; SWOG=Southwest Oncology Group
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